Novartis reaches a $57 billion licensing deal.

On September 15, local time, Swiss pharmaceutical giant Novartis signed a licensing agreement with biotechnology company Monte Rosa worth up to $5.7 billion for the development of drugs to treat immune-mediated diseases. According to the agreement, Monte Rosa will receive a prepayment of $120 million. The company's stock price surged 50% in pre-market trading.